[Amphastar] February 2026 Monthly Revenue NT$2.238 Billion (YoY +131.5%)
Amphastar (1795) announced astonishing financial results, with February 2026 monthly revenue soaring to NT$2.238 billion, representing a significant year-on-year increase of 131.5%. As a leading generic drug manufacturer in the Asia-Pacific region, this strong performance is likely driven by the success of high-value products such as addiction treatment drugs in overseas markets.
📋 Article Processing Timeline
- 📰 Published: February 1, 2026 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (1559h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:18 (16h 18m after Collected)
Company Code: 1795
Company Name: Amphastar Pharmaceuticals
Industry: Biotechnology and Medical Industry
Data Month/Year: 2026-02
Current Month Revenue: 2,238,173 Thousand NTD (NT$2.238 Billion)
Year-on-year Change: +131.5%
Company Name: Amphastar Pharmaceuticals
Industry: Biotechnology and Medical Industry
Data Month/Year: 2026-02
Current Month Revenue: 2,238,173 Thousand NTD (NT$2.238 Billion)
Year-on-year Change: +131.5%
FAQ
What was Amphastar Pharmaceuticals' revenue in February 2026?
Amphastar Pharmaceuticals reported a revenue of NT$2.238 Billion in February 2026.
How did Amphastar's February 2026 revenue compare to the previous year?
Amphastar's revenue in February 2026 showed a significant year-on-year increase of +131.5%.
What is the company code for Amphastar Pharmaceuticals?
The company code for Amphastar Pharmaceuticals is 1795.
In which industry sector does Amphastar Pharmaceuticals operate?
Amphastar Pharmaceuticals operates within the Biotechnology and Medical Industry sector.
What was the exact revenue figure in Thousand NTD for Amphastar in February 2026?
The exact revenue figure for Amphastar in February 2026 was 2,238,173 Thousand NTD.